Literature DB >> 17011829

Analysis of myocardial perfusion or myocardial function for detection of regional myocardial abnormalities. An echocardiographic multicenter comparison study using myocardial contrast echocardiography and 2D echocardiography.

Rainer Hoffmann1, Adrian C Borges, Jaroslaw D Kasprzak, Stephan von Bardeleben, Christian Firschke, Christian Greis, Marc Engelhardt, Harald Becher, Jean Louis Vanoverschelde.   

Abstract

BACKGROUND: Echocardiography based myocardial perfusion imaging and regional wall motion analysis are used for evaluation of coronary artery disease and regional myocardial abnormalities. AIM: This study sought to compare myocardial contrast echocardiography (MCE) and 2D echocardiography with regard to interobserver variability and detection of regional myocardial abnormalities.
METHODS: In 70 patients evenly distributed between three ejection fraction groups based on biplane cineventriculography ( > 55%, 35-55%, < 35%), unenhanced and contrast enhanced 2D echocardiography and myocardial contrast echocardiography (MCE; SonoVue; Bracco) were performed. Regional wall motion and myocardial perfusion were assessed referring to a 16 segment model. Interobserver agreement (IOA) among 2 readers was determined within each imaging modality. To define a standard of truth for the presence of segmental myocardial disease an independent expert-panel decision was obtained based on clinical data, ECG, coronary angiography and blinded information from the imaging modalities.
RESULTS: Regional wall motion assessment was possible in 98.1% of segments using contrast enhanced 2D echocardiography and in 87.2% using unenhanced 2D echocardiography (p < 0.001), while perfusion assessment was possible in 90.1% of segments (p < 0.001). IOA on presence of any regional wall motion abnormality expressed as Kappa coefficient was 0.71 (95% CI 0.53-0.89) for contrast enhanced echocardiography and 0.37 (95% CI 0.14-0.59) for unenhanced echocardiography. IOA on presence of any perfusion abnormality was 0.53 (95% CI 0.34-0.73). For MCE there was high IOA for the apical segments (kappa = 0.57) and lower IOA for the basal segments (kappa=0.14), while no such gradient was found for the IOA on wall motion abnormalities. Mean accuracy to detect expert-panel defined myocardial abnormalities was 80.6% for unenhanced echocardiography, 85.0% for contrast enhanced 2D echocardiography and 80.6% for MCE.
CONCLUSIONS: MCE is inferior to contrast enhanced 2D echocardiography with regard to visibility of all LV segments and appears slightly inferior with regards to IOA, while both are superior to unenhanced 2D echocardiography. The methods demonstrated high accuracy in detection of panel defined regional myocardial abnormalities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011829     DOI: 10.1016/j.euje.2006.07.009

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  4 in total

1.  Assessment of Skeletal Muscle Perfusion using Contrast-Enhanced Ultrasonography: Technical Note.

Authors:  Adnan I Qureshi; Muhammad A Saleem; Emrah Aytac; Shawn S Wallery
Journal:  J Vasc Interv Neurol       Date:  2017-01

2.  Evaluation of left ventricular myocardial mechanics by three-dimensional speckle tracking echocardiography in the patients with different graded coronary artery stenosis.

Authors:  Lin Li; Ping-Yang Zhang; Hong Ran; Jing Dong; Ling-Ling Fang; Qian-Shan Ding
Journal:  Int J Cardiovasc Imaging       Date:  2017-04-28       Impact factor: 2.357

3.  [Diagnostics and therapy of ischemia in chronic stable angina pectoris. Role of echocardiography].

Authors:  R S von Bardeleben; K Tiemann
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

Review 4.  Use of expert panels to define the reference standard in diagnostic research: a systematic review of published methods and reporting.

Authors:  Loes C M Bertens; Berna D L Broekhuizen; Christiana A Naaktgeboren; Frans H Rutten; Arno W Hoes; Yvonne van Mourik; Karel G M Moons; Johannes B Reitsma
Journal:  PLoS Med       Date:  2013-10-15       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.